Specifically, HSP90 inhibition decreases PD-L1 and PD-L2 expression in tumor cells34 and makes immune-refractory tumors susceptible to adoptive T-cell transfer and PD-1 blockade immunotherapies35. Here, PDCD1 is linked to neoplasm.